Description
Anti-Semaphorin 4D Antibody, Non-Fucosylated (BioBet-1275ZP) is a humanized monoclonal IgG antibody against Semaphorin 4D. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer; Multiple Sclerosis; Solid Tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Semaphorin 4D antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SEMA4D
Full Name
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
Alternative Names
SEMA4D; sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D; CD100; SEMAJ; coll-4; C9orf164; M-sema-G; semaphorin-4D; A8; GR3; BB18; sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, 4D
Gene ID
10507
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with SEMA4D include Autoimmune Vasculitis and Osteonecrosis Of The Jaw.
Related Pathways
Its related pathways are Guidance Cues and Growth Cone Motility and Axon guidance.
Function
PLXNB1 and PLXNB2 are cell surface receptors that play an important role in cell-cell signaling. Regulates the development of GABAergic synapses (through similarity). Promotes the development of inhibitory synapses in a plxnb1-dependent manner (through similarity). The activation of PLXNB1 regulates the complexity and branching of developing neuronal processes in hippocampal neurons, and the interaction with PLXNB1 mediates the activation of RHOA. Promote the migration of cerebellar granule cells. Acts in the immune system; induces b-cell aggregation and improves its viability (in vitro). By activating PTK2B/PYK2, SRC and phosphatidylinositol 3-kinase akt pathway, endothelial cell migration is induced.
Post-translational modifications
1.Glycosylation at Asn49, Asn77, Asn139, Asn191, Asn329, Asn379, Asn419, Asn613, Asn632, Thr657, Thr663, Ser666, Thr670, Thr716, and Ser722 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1275ZP
Description
VX15/2503 is a novel monoclonal antibody that blocks the activity of SEMA4D. Preclinical testing has demonstrated beneficial effects of anti-SEMA4D treatment in a variety of neurodegenerative disease models. VX15/2503 was well tolerated and no Maximum Tolerated Dose (MTD) was reached.
Antibody Indication
Cancer; Multiple Sclerosis; Solid Tumors
Cancer; Multiple Sclerosis; Solid Tumors
